Establishment of a VSV-Based Pseudovirus Platform for In Vitro and In Vivo Evaluation of Nipah Vaccine-Induced Neutralizing Responses
Viruses · 2025
DOI: 10.3390/v17111429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Seong Eun Bae und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Immunology, Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea. Hauptthemen laut MEDLINE: Nipah Virus, Antibodies, Neutralizing, Henipavirus Infections, Viral Vaccines. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gachon University Research Fund of 2022, The Government-wide R&D to Advance Infectious Disease Prevention and Control, The Government-wide R&D to Advance Infectious Disease Prevention and Control, Republic of Korea.
Abstract (Originalsprache)
The Nipah virus (NiV) is a zoonotic pathogen characterized by high fatality rates and pandemic potential, whereby there is an urgent need for developing safe and effective vaccines. However, the evaluation of NiV vaccine-induced immunity is hindered by the requirement of Biosafety Level-4 (BSL-4) containment. In this study, we developed a recombinant vesicular stomatitis virus (rVSV)-based pseudovirus-expressing NiV fusion (F) and attachment (G) glycoproteins using a luciferase reporter gene for bioluminescence detection. This pseudovirus was optimized for production in BHK-21 (WI-2) cells, and simultaneous incorporation of NiV-F and NiV-G onto the surface of the pseudotyped virus was confirmed via immunoprecipitation and Western blotting. We evaluated our pseudovirus-based neutralization assay using NiV-F-immunized mouse sera and a commercial anti-NiV-G antibody, confirming robust neutralization by the latter. To establish a BSL-2-compatible model for evaluating in vivo protective efficacy, we performed in vivo imaging, which revealed a marked reduction in the luminescence signal in NiV-G-immunized mice compared to naïve controls, indicating vaccine-induced protection. Our study established an integrated in vitro and in vivo pseudovirus platform using rVSV that enables safe, quantitative, and BSL-2-compatible evaluation of NiV vaccine candidates. This model offers a valuable tool for preclinical screening of vaccine-induced neutralizing antibody responses and protective efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Immunology, Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.
- Department of Bio-Medical Sciences, Gachon University, GAIST, Incheon 21936, Republic of Korea.
- Department of Microbiology, Gachon University College of Medicine, Incheon 21936, Republic of Korea.
- Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, Republic of Korea.
ORCID-Profile: Seong Eun Bae, Kee-Jong Hong, Jae-Ouk Kim
Förderung
- Gachon University Research Fund of 2022
- The Government-wide R&D to Advance Infectious Disease Prevention and Control
- The Government-wide R&D to Advance Infectious Disease Prevention and Control, Republic of Korea
Zitieren
APA
Bae, S. E., Yoon, M., Moon, Y., Kim, M. J., Kim, J. I., Hong, K. J., & Kim, J. O. (2025). Establishment of a VSV-Based Pseudovirus Platform for In Vitro and In Vivo Evaluation of Nipah Vaccine-Induced Neutralizing Responses. Viruses. https://doi.org/10.3390/v17111429
Vancouver
Bae SE, Yoon M, Moon Y, Kim MJ, Kim JI, Hong KJ, et al. Establishment of a VSV-Based Pseudovirus Platform for In Vitro and In Vivo Evaluation of Nipah Vaccine-Induced Neutralizing Responses. Viruses. 2025. doi:10.3390/v17111429
BibTeX
@article{Bae2025,
author = {Bae, Seong Eun and Yoon, Minhyuk and Moon, Younghye and Kim, Min Jung and Kim, Jeong-In and Hong, Kee-Jong and Kim, Jae-Ouk},
title = {Establishment of a VSV-Based Pseudovirus Platform for In Vitro and In Vivo Evaluation of Nipah Vaccine-Induced Neutralizing Responses},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17111429}
}
EUVIMED